Literature DB >> 2327784

In vitro activities of tosufloxacin, temafloxacin, and A-56620 against pathogens of diarrhea.

J P Bryan1, C Waters, J Sheffield, R E Krieg, P L Perine, K Wagner.   

Abstract

Tosufloxacin (A-60969 HCl), a new quinolone with broad activity against gram-positive and anaerobic organisms, was compared in vitro with other quinolones against bacterial pathogens of diarrhea. Tosufloxacin was the most active agent against Salmonella spp., Shigella spp., Campylobacter spp., Aeromonas hydrophila, and Vibrio spp. Temafloxacin (A-62254) also demonstrated good activity against these organisms.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2327784      PMCID： PMC171591          DOI： 10.1128/AAC.34.2.368

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Efficacy of ciprofloxacin in the treatment of chronic typhoid carriers.

Authors:  C Ferreccio; J G Morris; C Valdivieso; I Prenzel; V Sotomayor; G L Drusano; M M Levine
Journal:  J Infect Dis       Date:  1988-06       Impact factor: 5.226

2.  In vitro activities of lomefloxacin and temafloxacin against pathogens causing diarrhea.

Authors:  J Segreti; J A Nelson; L J Goodman; R L Kaplan; G M Trenholme
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

3.  Clinical efficacy of ciprofloxacin compared with placebo in bacterial diarrhea.

Authors:  H E Pichler; G Diridl; K Stickler; D Wolf
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

4.  Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for travelers' diarrhea. A placebo-controlled, randomized trial.

Authors:  C D Ericsson; P C Johnson; H L Dupont; D R Morgan; J A Bitsura; F J de la Cabada
Journal:  Ann Intern Med       Date:  1987-02       Impact factor: 25.391

Review 5.  Problems in salmonellosis: rationale for clinical trials with newer beta-lactam agents and quinolones.

Authors:  J P Bryan; H Rocha; W M Scheld
Journal:  Rev Infect Dis       Date:  1986 Mar-Apr

Review 6.  Antimicrobial therapy for enteric infections and typhoid fever: state of the art.

Authors:  G T Keusch
Journal:  Rev Infect Dis       Date:  1988 Jan-Feb

7.  Use of norfloxacin to treat chronic typhoid carriers.

Authors:  E Gotuzzo; J G Guerra; L Benavente; J C Palomino; C Carrillo; J Lopera; F Delgado; D R Nalin; J Sabbaj
Journal:  J Infect Dis       Date:  1988-06       Impact factor: 5.226

8.  Open, prospective study of the clinical efficacy of ciprofloxacin.

Authors:  C A Ramirez; J L Bran; C R Mejia; J F Garcia
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

9.  Comparative in vitro activities of aztreonam, ciprofloxacin, norfloxacin, ofloxacin, HR 810 (a new cephalosporin), RU28965 (a new macrolide), and other agents against enteropathogens.

Authors:  H Goossens; P De Mol; H Coignau; J Levy; O Grados; G Ghysels; H Innocent; J P Butzler
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

10.  Campylobacter enteritis in the United States. A multicenter study.

Authors:  M J Blaser; J G Wells; R A Feldman; R A Pollard; J R Allen
Journal:  Ann Intern Med       Date:  1983-03       Impact factor: 25.391
View more
  7 in total

1.  Characterization of high-level quinolone resistance in Campylobacter jejuni.

Authors:  T D Gootz; B A Martin
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

2.  In vitro antimicrobial susceptibilities of Yersinia enterocolitica and related species isolated from slaughtered pigs and pork products.

Authors:  J Kwaga; J O Iversen
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

3.  In vitro activities of cephalosporins and quinolones against Escherichia coli strains isolated from diarrheic dairy calves.

Authors:  J A Orden; J A Ruiz-Santa-Quiteria; S García; D Cid; R De La Fuente
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

4.  Cloning and nucleotide sequence of the Campylobacter jejuni gyrA gene and characterization of quinolone resistance mutations.

Authors:  Y Wang; W M Huang; D E Taylor
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

5.  Evidence for an efflux pump in multidrug-resistant Campylobacter jejuni.

Authors:  E Charvalos; Y Tselentis; M M Hamzehpour; T Köhler; J C Pechere
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

Review 6.  Future directions in antimicrobial chemotherapy.

Authors:  R Janknegt
Journal:  Pharm Weekbl Sci       Date:  1992-08-21

7.  In vitro activities of enoxacin, enrofloxacin, sparfloxacin, and ciprofloxacin against Escherichia coli strains isolated from diarrheic lambs and kids.

Authors:  D Cid; S Piriz; J A Ruiz-Santa-Quiteria; J Valle; S Garcia; S Vadillo; R de la Fuente
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.